BriSTAR Immunotech to Present New Cell Therapy for AML at AACR Special Conference on AML and MDS

TORONTO, Canada And BEIJING, January 20, 2023 /PRNewswire/ — BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR ) special conference on acute myeloid leukemia and myelodysplastic syndrome, ongoing January 23-25, 2023in Austin, Texas.

“The data show that our LILRB4 STAR-T cell therapy shows potent antitumor activity against AML in preclinical models,” said Dr. James Pan, CEO of BriSTAR Immunotech. “These results support our strategy to maximize the potential of our unique STAR-T technology platform.”

Presentation details:

Abstract title: Development of synthetic biparatopic LILRB4 T-cell receptor and antigen receptor (STAR) T-cells for the treatment of acute myeloid leukemia (AML)
Presenter: Dr. James Pan
Appointment: Tuesday 24 January 2023 7:15pm – 9:30pm CST
The full abstract will be available here. An electronic copy of the poster is available upon request EMAIL: [email protected].

About LILRB4 STAR-T

BriSTAR Immunotech has developed LILRB4 STAR-T cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). This new cell therapy drug candidate was developed using BriSTAR’s STAR-T platform to introduce the LILRB4-targeted biparatopic STAR gene into autologous T cells with a lentiviral gene transduction approach. This next-generation T-cell therapy uses two novel nano-antibodies that bind to different epitopes and fuse with the alpha and beta chains of the STAR structure, respectively. This gives LILRB4 START-T improved antigen involvement and increased cytotoxicity against this highly aggressive AML. In the December 2022the LILRB4 STAR-T program has received orphan drug designation from the US FDA.

About Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. AML occurs when a bone marrow cell suddenly develops genetic abnormalities. It is highly heterogeneous with limited treatment options and poor prognosis. AML is the most common acute leukemia in adults, with an incidence of more than 20,000 cases per year in the United States only, and China ranked among the top three in the world in terms of the number of AML cases and deaths, with 13,200 and 7,100 cases, respectively. For patients with relapsed/refractory AML, there is no treatment that significantly extends survival by 5-9 months.

About the STAR-T platform

BriSTAR Immunotech’s synthetic TCR and antigen receptor (STAR)-T cell therapy technology platform is highly effective in building a product pipeline for both hematologic and solid cancers. STAR-T has the characteristics of natural T cells, such as sensitive target engagement and strong tumor infiltration, and offers a natural framework for engineering dual-targeted T cell products.

In the September 2022, an Investigational New Drug Application (IND) for CD19/CD20 STAR-T cell injection (search code: HXYT-001) was granted by the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA) , for the treatment of relapsed/refractory non-Hodgkin lymphoma (B-NHL). In addition, STAR-T exploratory clinical trials have been initiated for several types of solid tumors.

About BriSTAR Immunotech

BriSTAR Immunotech Ltd is a clinical-stage cell therapy company established in 2018, focusing on developing better T-cell based therapies for the treatment of cancer and viral infections. The Company has two proprietary technology platforms, STAR-T and enTCR-T. STAR-T, like CAR-T is HLA independent, but uses a complete TCR signaling complex to engage and kill cancer cells. EnTCR-T activates a costimulatory signaling, in addition to the TCR complex, to eliminate viral infections. Our current pipeline includes product candidates indicated for AML and solid tumors as well as viral infections. Our lead product, a dual-targeted STAR-T CD19/CD20 candidate, is currently in clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

SOURCE Bristar Immunotech Limited

Add a Comment

Your email address will not be published. Required fields are marked *